Boston Scientific (BSX) Says CHAMPION-AF Trial Meets All Primary Endpoints

Boston Scientific Corporation (NYSE:BSX) is one of the 10 Best 52-Week Low NYSE Stocks to Buy Now.

On March 29, 2026, Boston Scientific Corporation (NYSE:BSX) announced that its CHAMPION-AF clinical trial met all primary and secondary safety and efficacy endpoints. The study evaluated the WATCHMAN FLX device versus NOACs for stroke risk reduction in patients with non-valvular atrial fibrillation. The company said the device showed a 45% relative reduction in non-procedural bleeding risk and a 34% reduction when including procedural bleeding, while achieving non-inferiority on the primary efficacy endpoint. Results were presented at the American College of Cardiology’s Annual Scientific Session and published in The New England Journal of Medicine.

On March 26, 2026, Goldman Sachs lowered its price target on Boston Scientific Corporation (NYSE:BSX) to $93 from $98 and maintained a Buy rating, reflecting more moderate growth assumptions and a more risk-adjusted outlook. Goldman Sachs said positive data from CHAMPION-AF and increasing physician and investor confidence could support further upside.

Boston Scientific (BSX) Says CHAMPION-AF Trial Meets All Primary Endpoints

Pixabay/Public domain

On March 24, 2026, Evercore ISI added Boston Scientific Corporation (NYSE:BSX) to its “Tactical Outperform” list with a $96 price target, citing upcoming data presentations as a potential catalyst.

Boston Scientific Corporation (NYSE:BSX) develops and markets medical devices across MedSurg and Cardiovascular segments globally.

While we acknowledge the risk and potential of BSX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BSX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.